Cite
Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending.
MLA
Mulligan, Casey B. “Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending.” NBER Working Papers, no. 31622–31724, Sept. 2023, pp. 1–20. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=172878646&authtype=sso&custid=ns315887.
APA
Mulligan, C. B. (2023). Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending. NBER Working Papers, 31622–31724, 1–20.
Chicago
Mulligan, Casey B. 2023. “Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending.” NBER Working Papers, no. 31622–31724 (September): 1–20. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=172878646&authtype=sso&custid=ns315887.